Compare ZYME & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | WEN |
|---|---|---|
| Founded | 2003 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2022 | 2000 |
| Metric | ZYME | WEN |
|---|---|---|
| Price | $25.02 | $8.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 22 |
| Target Price | ★ $38.90 | $8.84 |
| AVG Volume (30 Days) | 424.9K | ★ 9.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $105,965,000.00 | ★ $2,176,891,000.00 |
| Revenue This Year | $183.10 | $2.26 |
| Revenue Next Year | N/A | $0.94 |
| P/E Ratio | ★ N/A | $29.72 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $13.48 | $6.07 |
| 52 Week High | $29.75 | $10.84 |
| Indicator | ZYME | WEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 61.32 |
| Support Level | $24.79 | $7.84 |
| Resistance Level | $27.19 | $8.74 |
| Average True Range (ATR) | 1.02 | 0.41 |
| MACD | 0.34 | 0.12 |
| Stochastic Oscillator | 76.29 | 85.34 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.